April 25, 2026 — Gavi, the Vaccine Alliance, has announced a significant reduction in the rollout of malaria vaccines across 25 African countries due to cuts in U.S. International aid funding. The decision, disclosed by Gavi’s CEO Sania Nishtar during a briefing from Rwanda, reflects the direct impact of diminished financial support on global immunization efforts targeting one of the world’s most deadly infectious diseases.
According to Nishtar, the malaria vaccination program has experienced the most severe funding reductions among Gavi’s initiatives. The alliance has revised its goal of achieving 85% vaccine coverage in participating countries by 2030 downward to 70%. This adjustment is expected to diminish the projected public health impact of the campaign.
Gavi had previously estimated that widespread deployment of the malaria vaccine could prevent approximately 180,000 deaths over the initiative’s timeframe. However, with scaled-back implementation, Nishtar warned that the funding shortfall “will likely result in the loss of tens of thousands of children’s lives.”
Malaria remains a leading cause of mortality among children in Africa, responsible for an estimated 600,000 deaths annually, the majority occurring in young children across the continent. The vaccine, which has been piloted and expanded in recent years, represents a critical tool in reducing severe illness and death from the disease.
The funding constraints stem from broader reductions in U.S. Contributions to international health programs, which have disrupted supply chains and delayed vaccine deliveries in several participating nations. Gavi continues to work with national governments and partners to maintain essential immunization services despite the financial challenges.
Health experts emphasize that sustained investment in malaria prevention — including vaccination, insecticide-treated nets, and timely treatment — is essential to maintaining progress against a disease that continues to burden vulnerable populations. The current setback underscores the fragility of global health gains when faced with shifting donor priorities.
